肝门静脉窦性血管病合并非门静脉高压性腹水的临床病理特点及治疗初探

张玉姣; 王秀红; 郑英; 马安林

doi:10.3969/j.issn.1001-5256.2022.09.029

肝门静脉窦性血管病合并非门静脉高压性腹水的临床病理特点及治疗初探

DOI: 10.3969/j.issn.1001-5256.2022.09.029

张玉姣^1a,
王秀红^1b,
郑英^{1a, 2, , ,},
马安林^1a, , ,

1a.
中日友好医院感染疾病科，北京 100029
1b.
中日友好医院病理科，北京 100029
2.
中国人民解放军联勤保障部队第九四〇医院消化内科，兰州 730050

基金项目:

国家重点研发计划 (2020YFC200480)

伦理学声明：本报告已获得患者知情同意。

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：张玉姣、郑英参与了研究数据的获取分析解释过程并起草文章；王秀红、马安林参与修改文章关键内容。

详细信息

通信作者:
郑英，13919934061@139.com

马安林，maanlinjc@163.com

计量
- 文章访问数: 700
- HTML全文浏览量: 339
- PDF下载量: 46
- 被引次数: 0
出版历程
- 收稿日期: 2022-01-15
- 录用日期: 2022-02-15
- 出版日期: 2022-09-20

Clinicopathological features and treatment of hepatic porto-sinusoidal vascular disease with non-portal hypertensive ascites: A preliminary study

Yujiao ZHANG^1a,
Xiuhong WANG^1b,
Ying ZHENG^{1a, 2
, ,
,},
Anlin MA^{1a
, ,
,}

1a.
Department of Infectious Diseases, China-Japan Friendship Hospital, Beijing 100029, China
1b.
Department of Pathology, China-Japan Friendship Hospital, Beijing 100029, China
2.
Department of Gastroenterology, The 940 Hospital of Joint Logistic Support Force of PLA, Lanzhou 730050, China

Research funding:

National Key R & D Program of China (2020YFC200480)

More Information

Corresponding author: ZHENG Ying, 13919934061@139.com(ORCID: 0000-0002-2433-5484); MA Anlin, maanlinjc@163.com(ORCID: 0000-0002-9661-1441)

摘要

- 肝门静脉窦性血管病 /
- 腹水 /
- 高血压，门静脉 /
- 治疗学
- Porto-Sinusoidal Vascular Disease /
- Ascites /
- Hypertension, Portal /
- Therapeutics

HTML全文

注：a~c为病例1，汇管区未见纤维化，可见门静脉，但其口径减小；d~f为病例2，汇管区未见纤维化，相应口径门静脉消失，代之以多个薄壁小血管。a、d，HE染色，显示汇管区门静脉，×200；b、e，网织+Masson染色，显示汇管区纤维化程度，×200；c、f，CD34免疫组织化学染色，显示血管，×200。

图 1 患者的肝脏病理特点(细针穿刺活检)

Figure 1. Liver pathological features of patients (fine needle biopsy)

下载: 全尺寸图片幻灯片

表 1 患者的腹水特点

Table 1. Characteristics of ascites

病例	SAAG (g/L)	比重	黎氏试验	细胞总数	有核细胞数(mm³)	单核比例(%)	糖(mmol/L)	氯(mmol/L)	乳酸脱氢酶(U/L)	血清白蛋白(g/L)
1	8	1.025	+	1070	70	98	6.59	106	84	33.1
2	7	1.021	±	1200	150	95	12.35	111	210	30.7
注：SAAG，血清腹水白蛋白梯度。

下载: 导出CSV

参考文献(16)

[1]	KMEID M, LIU X, BALLENTINE S, et al. Idiopathic non-cirrhotic portal hypertension and porto-sinusoidal vascular disease: review of current data[J]. Gastroenterology Res, 2021, 14(2): 49-65. DOI: 10.14740/gr1376.
[2]	de GOTTARDI A, RAUTOU PE, SCHOUTEN J, et al. Porto-sinusoidal vascular disease: proposal and description of a novel entity[J]. Lancet Gastroenterol Hepatol, 2019, 4(5): 399-411. DOI: 10.1016/S2468-1253(19)30047-0.
[3]	WÖRAN K, SEMMLER G, JACHS M, et al. Clinical course of porto-sinusoidal vascular disease is distinct from idiopathic noncirrhotic portal hypertension[J]. Clin Gastroenterol Hepatol, 2022, 20(2): e251-e266. DOI: 10.1016/j.cgh.2020.11.039.
[4]	HERNÁNDEZ-GEA V, BAIGES A, TURON F, et al. Idiopathic portal hypertension[J]. Hepatology, 2018, 68(6): 2413-2423. DOI: 10.1002/hep.30132.
[5]	HERNÁNDEZ-GEA V, CAMPRECIÓS G, BETANCOURT F, et al. Co-expression gene network analysis reveals novel regulatory pathways involved in porto-sinusoidal vascular disease[J]. J Hepatol, 2021, 75(4): 924-934. DOI: 10.1016/j.jhep.2021.05.014.
[6]	CARNEVALE R, RAPARELLI V, NOCELLA C, et al. Gut-derived endotoxin stimulates factor VⅢ secretion from endothelial cells. Implications for hypercoagulability in cirrhosis[J]. J Hepatol, 2017, 67(5): 950-956. DOI: 10.1016/j.jhep.2017.07.002.
[7]	LEONARDI F, MARIA N, VILLA E. Anticoagulation in cirrhosis: a new paradigm?[J]. Clin Mol Hepatol, 2017, 23(1): 13-21. DOI: 10.3350/cmh.2016.0110.
[8]	CERINI F, GONZALEZ JM, TORRES F, et al. Impact of anticoagulation on upper-gastrointestinal bleeding in cirrhosis. A retrospective multicenter study[J]. Hepatology, 2015, 62(2): 575-583. DOI: 10.1002/hep.27783.
[9]	GAO Y, LIU H, TANG F, et al. Efficacy and safety of anticoagulants in liver cirrhosis patients with portal vein thrombosis: A meta-analysis[J]. Clin Res Hepatol Gastroenterol, 2021, 45(2): 101649. DOI: 10.1016/j.clinre.2021.101649.
[10]	HIDE D, WARREN A, FERNÁNDEZ-IGLESIAS A, et al. Ischemia/reperfusion injury in the aged liver: the importance of the sinusoidal endothelium in developing therapeutic strategies for the elderly[J]. J Gerontol A Biol Sci Med Sci, 2020, 75(2): 268-277. DOI: 10.1093/gerona/glz012.
[11]	POSE E, TREBICKA J, MOOKERJEE RP, et al. Statins: Old drugs as new therapy for liver diseases?[J]. J Hepatol, 2019, 70(1): 194-202. DOI: 10.1016/j.jhep.2018.07.019.
[12]	BUNCHORNTAVAKUL C, REDDY KR. Pharmacologic management of portal hypertension[J]. Clin Liver Dis, 2019, 23(4): 713-736. DOI: 10.1016/j.cld.2019.06.004.
[13]	HAN Y, CHEN J, QIU M, et al. Predicting long-term ischemic events using routine clinical parameters in patients with coronary artery disease: The OPT-CAD risk score[J]. Cardiovasc Ther, 2018, 36(5): e12441. DOI: 10.1111/1755-5922.12441.
[14]	KUMAR S, GRACE ND, QAMAR AA. Statin use in patients with cirrhosis: a retrospective cohort study[J]. Dig Dis Sci, 2014, 59(8): 1958-1965. DOI: 10.1007/s10620-014-3179-2.
[15]	MUÑOZ AE, POLLARSKY FD, MARINO M, et al. Addition of statins to the standard treatment in patients with cirrhosis: Safety and efficacy[J]. World J Gastroenterol, 2021, 27(28): 4639-4652. DOI: 10.3748/wjg.v27.i28.4639.
[16]	GIOIA S, NARDELLI S, RIDOLA L, et al. Causes and management of non-cirrhotic portal hypertension?[J]. Curr Gastroenterol Rep, 2020, 22(12): 56. DOI: 10.1007/s11894-020-00792-0.